Aldeyra Therapeutics (ALDX) Total Non-Current Liabilities (2013 - 2026)

Aldeyra Therapeutics' Total Non-Current Liabilities history runs 14 years deep, the most recent figure standing at $24.3 million for Q1 2026.

• Quarterly Total Non-Current Liabilities fell 17.81% year-over-year to $24.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $24.3 million (down 17.81% YoY) and the FY2025 annual result came in at $27.8 million, down 17.24% from the prior year.
• Total Non-Current Liabilities was $24.3 million for Q1 2026 at Aldeyra Therapeutics, down from $27.8 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $33.6 million in Q4 2024 and bottomed at $24.3 million in Q3 2023.
• A 5-year average of $28.7 million and a median of $28.5 million in 2023 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities jumped 50.74% — and 2026, when it dropped 17.81%.
• Aldeyra Therapeutics' Total Non-Current Liabilities stood at $30.3 million in 2022, then retreated by 5.78% to $28.5 million in 2023, then gained by 17.77% to $33.6 million in 2024, then dropped by 17.24% to $27.8 million in 2025, then dropped by 12.52% to $24.3 million in 2026.
• Business Quant data shows ALDX's Total Non-Current Liabilities at $24.3 million in Q1 2026, $27.8 million in Q4 2025, and $28.6 million in Q3 2025.